RBR-85bbp4尚未招募3 期
Clinical study to compare recombinant human growth hormone Cristália (r-hGH Cristália) versus Genotropin® in prepubertal children with growth deficiency due to deficiency of growth hormone.
ICF - Instituto de Ciências Farmaceuticas de Estudos e Pesquisas LTDA0 个研究点开始时间: 2015年9月9日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 4Y 至 14Y（—）
入选标准
- •Children aged 4 years and 13 years (for girls) and 14 years (for boys); Children prepubertal (Tanner stage 1); Bone age less than 11 years (for boys) and 9 years (for girls), documented by radiographs of the hand and wrist (will accept a radiograph performed within 6 months prior to enrollment in the study); Naïve children with growth hormone; Children diagnosed with disturbance in growth due to deficiency of growth hormone documented before initial treatment with r-hGH through: The height z score <-2.0 SD for age and sex; A response to a test stimulus GH release with peak blood 7 ng / ml in the presence of abnormalities morphostructural hypothalamic-pituitary region shown by Nuclear Magnetic Resonance (NMR) or; response to stimulus two tests of GH release with peak 7 ng / ml in the presence of a normal NMR (stimulating agents are acceptable insulin, clonidine, glucagon, arginine and L-dopa). Historical values of GH in blood up to 12 months prior to enrollment in the study will be acceptable. An MRI performed up to 2 years before inclusion in the study is acceptable; History of growth velocity below the mean for the normal population for at least 6 months prior to inclusion in the study, according to the table of VC Tanner (must be historical height data with a minimum of 6 months and maximum of 18 months. Researcher must ensure that the measurements were performed in a standardized way in standard stadiometer (rigid deck and rigid ruler); Baseline IGF-I -0.5 SD for age and sex (results provided by the central laboratory).
排除标准
- •Children aged <4 years; Children with clinical signs of puberty (breast / genitalia and pubic hair Tanner stage 2); Note: Children who enter puberty during treatment (breast development Tanner 2 / or testicles 4 ml or 2.5 cm in greatest diameter) shall be excluded; Other causes of disorder in children including growth in stature for gestational age (SGA), Turner syndrome, Prader-Willi syndrome, other causes; Children with closed epiphyses bone; Children with physical changes that prevent accurate measurement of height; Children with comorbidities that prevent normal growth. Patients with central hypothyroidism may be included, if well controlled with l-thyroxine, evidenced by normal free T4 dosages; dysmorphic syndrome; Presence of signs of skeletal dysplasia; Evidence of active malignancy or with less than two years of treatment considered curative; uncontrolled growth of benign intracranial tumors; Children with benign intracranial hypertension; Children with clinical evidence of malnutrition considered relevant to the discretion of the investigator; Children with Diabetes mellitus type 1 or 2; severe acute disease, including complications after heart surgery by thoracotomy, abdominal surgery, multiple accidental trauma or acute respiratory failure; concomitant chronic disease which may interfere with the analysis of the study (eg, hyperthyroidism / uncontrolled hypothyroidism, gastrointestinal diseases, cardio-respiratory diseases, liver failure, kidney failure, bone pathologies that can affect the growth, chronic inflammatory diseases and inborn errors of metabolism); Patients with hormone deficiency related diseases by panhypopituitarism may be included if properly controlled; MRI findings that may interfere with the study drug (examples: intracranial hypertension, tumors in the hypothalamic-pituitary region); Children with anti-GH antibodies;
- •Children undergoing treatment for the disorder or attention deficit hyperactivity disorder deficit hyperactivity disorder; Concomitant medication that could influence the secretion of growth (eg, estrogen, androgen, anabolic steroids, steroids, aromatase inhibitors) hormone. Physiological doses of corticosteroids for the treatment of pituitary deficiency are allowed as well as low-dose inhaled and / or nasal steroids for the treatment of asthma or chronic rhinitis (500mcg or less / day beclomethasone or equivalent); or known allergy to the study medications, or any of the excipients or thinner / solvent hypersensitivity; Participation in another clinical study within 3 months before study entry; Statement of legal limitation disability or parent / legal representative
研究者
相似试验
进行中（未招募）
不适用
Clinical study to compare recombinant human growth hormone Cristalia(r-hGH Cristalia) versus Genotropin® in prepubertal children withgrowth deficiency due to deficiency of growth hormone.Growth deficiency due to growth hormone deficiencyMedDRA version: 18.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-000446-56-Outside-EU/EEACristália Produtos Químicos Farmacêuticos Ltda.94
招募中
不适用
Investigation of the effect of recombinant human soluble thrombomodulin on the improvement of renal injury and mortality in septic patients with disseminated intravascular coagulatioseptic DICJPRN-UMIN000037245Sapporo Medical University200
已完成
2 期
A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGASmall for Gestational Age InfantNCT03221933Changchun GeneScience Pharmaceutical Co., Ltd.120
尚未招募
2 期
To study management of guggul and shallaki in janu sandhigatavata(degenerative osteoarthritis)CTRI/2024/04/066200Dr Apeksha Umeshchandra Kulkarni
已完成
不适用
Clinical trial for the treatment of pulmonary alveolar proteinosis by inhalation of recombinant human granulocyte-macrophage colony stimulating factor (GMCSF)Autoimmune (idiopathic) pulmonary alveolar proteinosisRespiratoryOther interstitial pulmonary diseasesISRCTN18931678iigata University Medical and Dental Hospital (Japan)40